Thyroid hormone for fibrotic lung diseases

OCR Number: OCR 6368

Description:

Thyroid hormone as a novel therapeutic agent in fibrotic lung diseases

- Idiopathic pulmonary fibrosis (IPF) is a lethal fibrotic lung disorder. The median survival of patients with IPF is 3.5-4 years from initial diagnosis, irrespective of treatment.
- Innovation:
  - Inhaled or aerosolized delivery of thyroid hormone to the lung – preliminary results demonstrate thyroid hormone resolves pulmonary fibrosis in animal models and increases survival
  - Integration of personalized medicine approach to target IPF patients with a highest likelihood for thyroid hormone therapy.
- IP Status: PCT/US 15/317,276
- Lead Innovator: Naftali Kaminski, M.D.

PI: Naftali Kaminski

Licensing Contact: John Puziss
john.puziss@yale.edu